A problem doesn’t go away if you ignore it, and liver cancer has been ignored by the general public for far too long. We’ve reached the point where liver cancer is the fastest increasing cause of cancer mortality in Australia. It also sits as the third most common cause of cancer death, worldwide....
You can help fight the fastest increasing cause of cancer mortality in Australia
A problem doesn’t go away if you ignore it, and liver cancer has been ignored by the general public for far too long. We’ve reached the point where liver cancer is the fastest increasing cause of cancer mortality in Australia. It also sits as the third most common cause of cancer death, worldwide. 1,643 people a day are dying of liver cancer.
The stats paint a very scary picture, but here at GMRF we see beyond the numbers and figures. The real impact of liver cancer is not in its numbers but in the countless lives it is devastating each day.
GMRF has established the only dedicated liver cancer research facilty in Queensland. This unit is not government funded and relies on the generous support of donors, community groups, and corporate partners.
We have established a clear vision for our cancer research:
- Our Mission: to change cancer from a death sentence to a treatable chronic illness within our lifetime.
- Our process: Targeting cancer on multiple fronts including immunotherapy research to re-engage the immune system to fight the cancer, and anti-metastasis research to stop the cancer spreading throughout the body.
Your support can change lives. Please donate today to help ensure this vital research can continue.
Current projectsView all projects
Here we use our knowledge of the immunology of liver cancer to develop ways to teach our immune system to target and kill the cancer. Our research focuses on developing liver cancer vaccines and other immune-stimulatory therapies to achieve this. Using genetically modified viruses as vaccines we...
Increasing evidence supports the concept that a specialized population of cancer cells within a tumour possess characteristics of self-renewal and have the ability to give rise to all cell types in a particular cancer. These 'cancer stem cells' also exhibit characteristics that render them resistant...
The Liver Cancer Unit published seven journal articles during the 2016-2017 Financial Year.
Jayachandran A., Dhungel B., Steel JC. (2016) Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in Hepatocellular Carcinoma. J Hematol. Oncol, 9(1):74. doi: 10.1186/s13045-016-0307-9.
Tögel L, Nightingale R, Chueh AC, Jayachandran A, Tran H, Phesse T, Wu R, Sieber OM, Arango D, Dhillon AS, Dawson MA, Diez-Dacal B, Gahman TC, Filippakopoulos P, Shiau AK, Mariadason JM. (2016) Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Mol Cancer Ther. 2016;15(6):1217-26. doi: 10.1158/1535-7163.
Jayachandran A, Prithviraj P, Lo PH, Walkiewicz M, Anaka M, Woods BL, Tan B, Behren A, Cebon J, McKeown SJ. (2016) Identifying and targeting determinants of melanoma cellular invasion. Oncotarget. 2016 5;7(27):41186-41202. doi: 10.18632/oncotarget.9227.
Dhungel B., Jayachandran A., Layton CJ., Steel JC. (2017) Seek and Destroy: Targeted Adeno-associated Viruses for Gene Delivery to Hepatocellular Carcinoma. Drug Del. 24(1):289-299. doi: 10.1080/10717544.2016.1247926
Mir N.*, Jayachandran A.*, Dhungel B., Shrestha R., Steel JC. (2017) Epithelial-to-Mesenchymal Transition: a Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma. Curr Cancer Drug Targets. 2017;17(8):698-706. doi: 10.2174/1568009617666170427104356. *Equal contributing Authors.
Wang H, Zhang R, Bridle KR, Jayachandran A, Thomas JA, Zhang W, Yuan J, Xu ZP, Crawford DH, Liang X, Liu X, Roberts MS. (2017) Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury. Sci Rep. 7:45374. doi: 10.1038/srep45374.
Chüeh AC, Liew MS, Russell PA, Walkiewicz M, Jayachandran A, Starmans MHW, Boutros PC, Wright G, Barnett SA, Mariadason JM, John T. (2017) Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget. 2017 23;8(43):74036-74048. doi: 10.18632/oncotarget.18198.
The Liver Cancer Unit has a number of local, national and international collaborations, including:
- Translational Research Insititute (TRI) – Brisbane
- Griffith University – Brisbane
- University Cincinnati (USA)
- US Naval Medical Research Center (USA),
- Ochsner Institute(USA)
Opportunities for students
The Liver Cancer Unit currently has two students completing their PhD as part of GMRF’s scholarship program. If you are interested in findng out more about this program please contact the Foundation on 07 3394 7284.
Contact us and we’ll reply as soon as we can.